The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMediumUpdated•Originally published 8 May 2026•Updated 8 May 2026•

1 min read

Odyssey Therapeutics Raises $279 Million in Upsized US IPO

Key Facts

1Biopharmaceutical company Odyssey Therapeutics raised $279 million in its upsized U.S. initial public offering.

Biopharmaceutical firm Odyssey Therapeutics has successfully raised $279 million in an upsized initial public offering on the U.S. stock market. The company's shares surged 11.1% in its market debut, bringing its total valuation to $899.9 million. Odyssey Therapeutics intends to utilize the proceeds to fund its ongoing operations and accelerate its research and development initiatives. This successful debut serves as a bullish indicator for the healthcare IPO sector, which has faced varying market conditions recently. The substantial capital injection provides the company with a significant runway to advance its clinical programs. Analysts are closely watching the stock's continued performance as a gauge for investor appetite in the broader Biotech space.

26 days ago

Version History

Version 126 days ago

What changed: Added the stock's first-day trading performance (11.1% increase) and the company's total market valuation.